Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Dexmedetomidine (DXM) is an alpha-2 adrenoreceptor agonist of interest in palliative care.1 2 It has been conventionally used in intensive care for sedation (with rousability) and refractory neuropathic pain, and ventilator weaning.3 There is minimal literature in palliative care, with case reports for use in refractory cancer pain, and as a sedative, and retrospective chart analyses of use for sedation in terminal heart failure.4–6
End-of-life-care drugs in palliative medicine are often given subcutaneously, with the syringe driver the tool of choice in multiple settings.7 A syringe driver allows multiple medications in a single syringe, if compatibility permits.7 Although DXM is well tolerated subcutaneously with minimal side effects,8 it is unclear whether it can be given along with other medications in a single syringe, which would expand utility. There are laboratory compatibility data in …
Contributors BT and PS designed the project. All authors created the admixtures. LM and PS analysed the results. BT wrote the manuscript. LM and PS provided critical input into the manuscript. All authors approved of the final version.
Funding Funding for the provision of the agents used in this study was provided by the Illawarra Shoalhaven Local Health District, Early Clinician Researcher Grant, awarded to the primary author.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.